Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies

Detalhes bibliográficos
Autor(a) principal: Casas, Carmen Phang Romero
Data de Publicação: 2022
Outros Autores: Albuquerque, Rita de Cássia Ribeiro de, Loureiro, Rafaela Borge, Gollner, Angela Maria, Freitas, Marina Gonçalves de, Duque, Graciela Paula do Nascimento, Viscondi, Juliana Yukari Kodaira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/213606
Resumo: Economic assessments are relevant to support the decision to incorporate more cost-effective strategies to reduce Cervical Cancer (CC) mortality. This systematic review analyzes the economic evaluation studies of CC prevention strategies (HPV DNA-based tests and conventional cytology) in low- and middle-income countries. Medline, EMBASE, CRD, and LILACS were searched for economic evaluation studies that reported cost and effectiveness measures of HPV DNA-based tests for CC screening and conventional cytology in women, without age, language, or publication date restrictions. Selection and data extraction were carried out independently. For comparability of results, cost-effectiveness measures were converted to international dollars (2019). Report quality was assessed using the CHEERS checklist. The Dominance Matrix Ranking (DRM) was used to analyze and interpret the results. The review included 15 studies from 12 countries, with cost-effectiveness analyzes from the health system's perspective and a 3% discount rate. The strategies varied in age and frequency of screening. Most studies used the Markov analytical model, and the cost-benefit threshold was based on the per capita GDP of each country. The sensitivity analysis performed in most studies was deterministic. The completeness of the report was considered sufficient in most of the items evaluated by CHEERS. The Dominance Interpretation (DRM) varied; in 6 studies, the HPV test was dominant, 5 studies showed a weak dominance evaluating greater effectiveness of the HPV test at a higher cost, yet in 2 studies conventional cytology was dominant. Although the context-dependent nature of economic evaluations, this review points out the challenge of methodological standardization in the analytical models.
id USP-19_3390f2a5cebcf0f726c16cf2c7b9c5ad
oai_identifier_str oai:revistas.usp.br:article/213606
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studiesEconomic evaluationsCervical cancerDNA tests for human papillomavirusEconomic assessments are relevant to support the decision to incorporate more cost-effective strategies to reduce Cervical Cancer (CC) mortality. This systematic review analyzes the economic evaluation studies of CC prevention strategies (HPV DNA-based tests and conventional cytology) in low- and middle-income countries. Medline, EMBASE, CRD, and LILACS were searched for economic evaluation studies that reported cost and effectiveness measures of HPV DNA-based tests for CC screening and conventional cytology in women, without age, language, or publication date restrictions. Selection and data extraction were carried out independently. For comparability of results, cost-effectiveness measures were converted to international dollars (2019). Report quality was assessed using the CHEERS checklist. The Dominance Matrix Ranking (DRM) was used to analyze and interpret the results. The review included 15 studies from 12 countries, with cost-effectiveness analyzes from the health system's perspective and a 3% discount rate. The strategies varied in age and frequency of screening. Most studies used the Markov analytical model, and the cost-benefit threshold was based on the per capita GDP of each country. The sensitivity analysis performed in most studies was deterministic. The completeness of the report was considered sufficient in most of the items evaluated by CHEERS. The Dominance Interpretation (DRM) varied; in 6 studies, the HPV test was dominant, 5 studies showed a weak dominance evaluating greater effectiveness of the HPV test at a higher cost, yet in 2 studies conventional cytology was dominant. Although the context-dependent nature of economic evaluations, this review points out the challenge of methodological standardization in the analytical models.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2022-07-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/21360610.1016/j.clinsp.2022.100080Clinics; Vol. 77 (2022); 100080Clinics; v. 77 (2022); 100080Clinics; Vol. 77 (2022); 1000801980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/213606/195692Copyright (c) 2023 Clinicsinfo:eu-repo/semantics/openAccessCasas, Carmen Phang RomeroAlbuquerque, Rita de Cássia Ribeiro deLoureiro, Rafaela BorgeGollner, Angela MariaFreitas, Marina Gonçalves deDuque, Graciela Paula do NascimentoViscondi, Juliana Yukari Kodaira2023-07-06T13:04:54Zoai:revistas.usp.br:article/213606Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:54Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
title Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
spellingShingle Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
Casas, Carmen Phang Romero
Economic evaluations
Cervical cancer
DNA tests for human papillomavirus
title_short Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
title_full Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
title_fullStr Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
title_full_unstemmed Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
title_sort Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies
author Casas, Carmen Phang Romero
author_facet Casas, Carmen Phang Romero
Albuquerque, Rita de Cássia Ribeiro de
Loureiro, Rafaela Borge
Gollner, Angela Maria
Freitas, Marina Gonçalves de
Duque, Graciela Paula do Nascimento
Viscondi, Juliana Yukari Kodaira
author_role author
author2 Albuquerque, Rita de Cássia Ribeiro de
Loureiro, Rafaela Borge
Gollner, Angela Maria
Freitas, Marina Gonçalves de
Duque, Graciela Paula do Nascimento
Viscondi, Juliana Yukari Kodaira
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Casas, Carmen Phang Romero
Albuquerque, Rita de Cássia Ribeiro de
Loureiro, Rafaela Borge
Gollner, Angela Maria
Freitas, Marina Gonçalves de
Duque, Graciela Paula do Nascimento
Viscondi, Juliana Yukari Kodaira
dc.subject.por.fl_str_mv Economic evaluations
Cervical cancer
DNA tests for human papillomavirus
topic Economic evaluations
Cervical cancer
DNA tests for human papillomavirus
description Economic assessments are relevant to support the decision to incorporate more cost-effective strategies to reduce Cervical Cancer (CC) mortality. This systematic review analyzes the economic evaluation studies of CC prevention strategies (HPV DNA-based tests and conventional cytology) in low- and middle-income countries. Medline, EMBASE, CRD, and LILACS were searched for economic evaluation studies that reported cost and effectiveness measures of HPV DNA-based tests for CC screening and conventional cytology in women, without age, language, or publication date restrictions. Selection and data extraction were carried out independently. For comparability of results, cost-effectiveness measures were converted to international dollars (2019). Report quality was assessed using the CHEERS checklist. The Dominance Matrix Ranking (DRM) was used to analyze and interpret the results. The review included 15 studies from 12 countries, with cost-effectiveness analyzes from the health system's perspective and a 3% discount rate. The strategies varied in age and frequency of screening. Most studies used the Markov analytical model, and the cost-benefit threshold was based on the per capita GDP of each country. The sensitivity analysis performed in most studies was deterministic. The completeness of the report was considered sufficient in most of the items evaluated by CHEERS. The Dominance Interpretation (DRM) varied; in 6 studies, the HPV test was dominant, 5 studies showed a weak dominance evaluating greater effectiveness of the HPV test at a higher cost, yet in 2 studies conventional cytology was dominant. Although the context-dependent nature of economic evaluations, this review points out the challenge of methodological standardization in the analytical models.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-26
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213606
10.1016/j.clinsp.2022.100080
url https://www.revistas.usp.br/clinics/article/view/213606
identifier_str_mv 10.1016/j.clinsp.2022.100080
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/213606/195692
dc.rights.driver.fl_str_mv Copyright (c) 2023 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 77 (2022); 100080
Clinics; v. 77 (2022); 100080
Clinics; Vol. 77 (2022); 100080
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222767050653696